Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261

Richard Carvajal, M.D.

Director of Experimental Therapeutics and Melanoma Service

Dr. Richard Carvajal is the Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, his focus is on the development of novel therapies for patients with melanoma and other cancers, with the overall objective of controlling and curing these diseases.  To achieve this goal, he has used our increasing knowledge of the underlying biology of cancer to rapidly integrate this knowledge, novel-targeted and immunotherapeutic agents, and efficient trial design in order to improve the outcomes of cancer patients everywhere.

Richard’s melanoma research has included the study and treatment of uncommon clinical and molecular subsets of melanoma such as melanomas arising from the eye (uveal melanomas), from the mucosal surfaces of the body (mucosal melanomas), and from the palms of the hands, soles of the feet, or under the fingernails (acral melanomas).

In addition to his work at Columbia University Medical Center, he serves as the co-chair of the International Rare Cancer Initiative Uveal Melanoma working group, a joint initiative between the National Cancer Institute, the European Organization for Research and Treatment of Cancer, and the Cancer Research U.K. to enhance international collaboration in the conduct of clinical trials for uveal melanoma.  His research has been supported by the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, the Melanoma Research Foundation, the Empire Clinical Research Investigator Program, and the generous philanthropic support of our patients and their families. He has been an investigator or co-investigator on over 400 clinical trials and has authored or co-authored more than 100 peer-reviewed manuscripts, books, and book chapters.